A STUDY TO EVALUATE THE EFFICACY OF ORAL TERBINAFINE AND A COMBINATION OF ORAL TERBINAFINE AND TOPICAL SERTACONAZOLE IN TINEA CORPORIS PATIENTS ATTENDING DERMATOLOGY OUTPATIENT DEPARTMENT IN A TERTIARY CARE HOSPITAL, HYDERABAD
DOI:
https://doi.org/10.22159/ijcpr.2025v17i2.54212Keywords:
Tinea corporis, Oral terbinafine, Sertaconazole, 4-point rating scale, Clinical cure, Mycological cureAbstract
Objective: To evaluate the efficacy of Oral Terbinafine (250 mg) and a combination of oral terbinafine (250 mg) and topical sertaconazole (2%) in patients with Tinea corporis attending Dermatology Out Patient Department (OPD), in a tertiary care centre.
Methods: An open-labeled comparative study was conducted in Dermatology OPD at Osmania General Hospital for 12 mo. Patients diagnosed with tinea corporis were randomly assigned into two groups: Group A: 50 Patients received Oral Terbinafine (250 mg) and Group B: 50 Patients received combination of Oral Terbinafine (250 mg) and Topical Sertaconazole (2%) for 2 w. The patients were advised to come after 1st and 2nd w for follow-up visits.
Results: The study involved 100 patients with tinea corporis, with a mean age of 32.42±8.48 years in Group A and 33.38±7.76 years in Group B. Most participants were males (Group A – 62%, Group B – 80%). Clinical features (itching, burning, scaling, crusting, vesicles, pustules) showed a significant reduction in Group B compared to Group A after 2 w of treatment, with a statistically significant difference (P<0.000001). Lesion size decreased more in Group B (from 26.1±14.9 to 2.0±1.2) than in Group A (from 24.5±14.4 to 6.01±4.2), with a significant difference (P<0.0000001). All specimens in Group B were free of fungal growth.
Conclusion: Clinical cure and mycological cure were better with a Combination of Oral Terbinafine (250 mg) and Topical Sertaconazole (2%) than with Oral Terbinafine (250 mg) alone. Both drugs were well tolerated and no major adverse drug reactions were noted during the study period.
Downloads
References
Jartarkar SR, Patil A, Goldust Y, Cockerell CJ, Schwartz RA, Grabbe S. Pathogenesis immunology and management of dermatophytosis. J Fungi (Basel). 2021 Dec 31;8(1):39. doi: 10.3390/jof8010039, PMID 35049979, PMCID PMC8781719.
Rajagopalan M, Inamadar A, Mittal A, Miskeen AK, Srinivas CR, Sardana K. Expert consensus on the management of dermatophytosis in India (ectoderm India). BMC Dermatol. 2018 Jul 24;18(1):6. doi: 10.1186/s12895-018-0073-1, PMID 30041646, PMCID PMC6057051.
Gupta AK, Chaudhry M, Elewski B. Tinea corporis tinea cruris tinea nigra and piedra. Dermatol Clin. 2003 Jul;21(3):395-400. doi: 10.1016/s0733-8635(03)00031-7, PMID 12956194.
Sahoo AK, Mahajan R. Management of tinea corporis tinea cruris and tinea pedis: a comprehensive review. Indian Dermatol Online J. 2016 Mar-Apr;7(2):77-86. doi: 10.4103/2229-5178.178099, PMID 27057486, PMCID PMC4804599.
Naglot A, Shrimali S, Nath B, Gogoi H, Veer V, Chander J. Recent trends of dermatophytosis in Northeast India (Assam) and interpretation with published studies. Int J Curr Microbiol Appl Sci. 2015;4(11):111-20.
Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev. 1995 Apr;8(2):240-59. doi: 10.1128/CMR.8.2.240, PMID 7621400, PMCID PMC172857.
Faergemann J, Zehender H, Denouel J, Millerioux L. Levels of terbinafine in plasma stratum corneum dermis epidermis (without stratum corneum) sebum hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venereol. 1993 Aug;73(4):305-9. doi: 10.2340/000155557300304, PMID 7904107.
Van Der Schroeff JG, Cirkel PK, Crijns MB, Van Dijk TJ, Govaert FJ, Groeneweg DA. A randomized treatment duration finding study of terbinafine in onychomycosis. Br J Dermatol. 1992 Feb;126 Suppl 39:36-9. doi: 10.1111/j.1365-2133.1992.tb00008.x, PMID 1531927.
Goodfield MJ, Rowell NR, Forster RA, Evans EG, Raven A. Treatment of dermatophyte infection of the finger and toe nails with terbinafine (SF 86-327 Lamisil) an orally active fungicidal agent. Br J Dermatol. 1989 Dec;121(6):753-7. doi: 10.1111/j.1365-2133.1989.tb08217.x, PMID 2532927.
Poojary SA. Topical antifungals: a review and their role in current management of dermatophytoses. Clin Dermatol Rev. 2017;1(3) Suppl 1:S24-9. doi: 10.4103/CDR.CDR_34_17.
Croxtall JD, Plosker GL. Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs. 2009;69(3):339-59. doi: 10.2165/00003495-200969030-00009, PMID 19275277.
Sumitha A, Geetha M, Shashikala GH, Somashekar HS, Chandan KS. Efficacy and safety of 1% terbinafine hydrochloride versus 2% sertaconazole cream in the treatment of tinea corporis. Int J Basic Clin Pharmacol. 2017;4(3):474-8. doi: 10.18203/2319-2003.
Choudhary S, Bisati S, Singh A, Koley S. Efficacy and safety of terbinafine hydrochloride 1% cream vs. sertaconazole nitrate 2% cream in tinea corporis and tinea cruris: a comparative therapeutic trial. Indian J Dermatol. 2013 Nov;58(6):457-60. doi: 10.4103/0019-5154.119958, PMID 24249898, PMCID PMC3827518.
Chatterjee D, Ghosh SK, Sen S, Sarkar S, Hazra A, DE R. Efficacy and tolerability of topical sertaconazole versus topical terbinafine in localized dermatophytosis: a randomized observer-blind parallel-group study. Indian J Pharmacol. 2016 Nov-Dec;48(6):659-64. doi: 10.4103/0253-7613.194850, PMID 28066103, PMCID PMC5155466.
Selvan AT, Gutha G, Vijaybhaskar SR, Suthakaran R. Comparative evaluation of newer topical antifungal agents in the treatment of superficial fungal infections (tinea or dermatophytic). Int Res J Pharm. 2013;4(6):224-8. doi: 10.7897/2230-8407.04651.
Jerajani H, Janaki C, Kumar S, Phiske M. Comparative assessment of the efficacy and safety of sertaconazole (2%) cream versus terbinafine cream (1%) versus luliconazole (1%) cream in patients with dermatophytoses: a pilot study. Indian J Dermatol. 2013 Jan;58(1):34-8. doi: 10.4103/0019-5154.105284, PMID 23372210, PMCID PMC3555370.
Siddiqui SM, Phulari YJ, Hiremath RN, Patil C, Patel P. A clinic mycological evaluation of dermatophytic infections a single centre prospective observational study. Asian J Pharm Clin Res. 2022;15(4):122-6. doi: 10.22159/ajpcr.2022.v15i4.44454.
Shekar A, Mittal G, Chandane RD, Suranagi UD. A prospective randomized open-labeled parallel-group study to compare the efficacy of oral terbinafine versus oral terbinafine plus oral fluconazole in dermatophyte infections. Asian J Pharm Clin Res. 2023;16(5):104-8. doi: 10.22159/ajpcr.2023.v16i5.47224.
Published
How to Cite
Issue
Section
Copyright (c) 2025 SWATHI MIRYALA, M. SNEHA MANJU, PURAM GIRI RAJA, MAHESH KUMAR K.
This work is licensed under a Creative Commons Attribution 4.0 International License.